NCT02667574 2022-10-17
VISMONEO
University Hospital, Lille
Phase 2 Completed
Clinical Trials
16 trialsNCT03610022 2022-08-18
OPTIVISMO-1
University Hospital, Bordeaux
Phase 4 Completed
NCT03035188 2022-02-11
NICCI
SRH Wald-Klinikum Gera GmbH
Phase 2 Completed
NCT02436408 2021-10-28
VISORB
University of Michigan Rogel Cancer Center
Phase 4 Completed
NCT01556009 2020-11-02
Vismodegib
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT02371967 2020-10-09
ROSETT
Hoffmann-La Roche
Completed
NCT01700049 2019-05-23
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Mayo Clinic
Phase 2 Completed
NCT02674009 2019-05-13
NIELS
Hoffmann-La Roche
Completed
NCT02690948 2019-03-08
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Stanford University
Phase 1/2 Completed
NCT02639117 2018-07-18
PDT-Vismo
University of Arizona
Phase 1 Completed
NCT01815840 2017-09-28
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
Hoffmann-La Roche
Phase 2 Completed
NCT00968981 2017-07-11
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Genentech, Inc.
Phase 1 Completed
NCT00833417 2015-05-20
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00959647 2015-01-07
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT01543581 2014-09-26
Erivedge
Loma Linda University
Phase 2 Completed
NCT01201915 2014-06-24
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed